Gastroenterology · IBS-DRegulatory Approvalregulatorymid-term

Aurobindo Pharma's ANDA213511 for Eluxadoline Receives AP Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma27 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/22/2026, 12:32:47 PM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's Abbreviated Approval of Aurobindo Pharma's Eluxadoline marks a significant development in the IBS-D treatment landscape, increasing competitive pressure on existing therapies. Pharma strategy teams must evaluate the implications for market share and pricing strategies as Aurobindo prepares to enter the market. Regulatory context from FDA (FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Aurobindo's entry on market share and pricing strategies for IBS-D therapies. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sponsor/company relevance (novartis). In Gastroenterology · IBS-D, 5 regulatory and 7 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from [Ad hoc announcement pursuant to Art.. This approval allows Aurobindo to enter the market for Eluxadoline, potentially increasing competition against existing IBS-D treatments.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, PMDA. The approval indicates a shift in the regulatory landscape for IBS-D treatments, which may influence future submissions and competitive strategies.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community) could weigh on Aurobindo Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Aurobindo's entry could disrupt pricing and market dynamics, potentially affecting revenue streams for current IBS-D therapies.
Upside for Aurobindo Pharma may improve if Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of Aurobindo's entry on market share and pricing strategies for IBS-D therapies.

What Would Change This Assessment

This becomes more urgent if Monitor for the launch timeline and any potential market responses from competitors.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Internet Pharmacy Warning Letters
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
[YAKKYOKUKATA]Press Release regarding international activities related to Pharmacopoeia posted
PMDAmedium relevance
Moderate corpus alignment
FDA document
View source

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartishigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
FDA Accepts Supplemental NDA for Linzess by AbbVie
Humanexa Signalsmedium relevance
Moderate corpus alignment
Resmetirom (Rezdiffra) Approved for MASH Treatment in Adults
Humanexa Signalsmedium relevance
Moderate corpus alignment

Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, an
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Eluxadoline

Commercial impact

medium

Aurobindo's entry could disrupt pricing and market dynamics, potentially affecting revenue streams for current IBS-D therapies.

Regulatory impact

medium

The approval indicates a shift in the regulatory landscape for IBS-D treatments, which may influence future submissions and competitive strategies.

What to watch

Monitor for the launch timeline and any potential market responses from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.